Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 (SEBI LODR Regulations), Camlin Fine Sciences has informed that on 15th May, 2021 the Shares Transfer/Administrative & Finance Committee (the Committee) of Camlin Fine Sciences (the Company), pursuant to the powers granted by the Board of Directors, has approved strategic investment in AlgalR NutraPharms (AlgalR) by way of acquisition of equity shares amounting to 69.33% of the existing paid?up share capital (Secondary Purchase). The Committee has also approved subscription to the equity shares of AlgalR (Primary Subscription). Upon consummation of the Secondary Purchase and Primary Subscription, the Company will hold 80% of the paid?up capital of AlgalR on a fully diluted basis. The Company will now be executing the Investment Agreement, Share Purchase Agreement and the incidental agreements / documents with AlgalR and its promoters / other shareholders. The details required under SEBI LODR Regulations are annexed.
The above information is a part of company’s filings submitted to BSE.
